Variability in Golimumab Exposure: A ‘Real-Life’ Observational Study in Active Ulcerative Colitis

BACKGROUND AND AIMS: Golimumab has been approved recently to treat refractory moderate-to-severe ulcerative colitis [UC]. To date it is not clear why a considerable fraction of patients do not respond, or lose initial response, to golimumab therapy. Our aim was to investigate whether a low golimumab...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Crohns Colitis
Hlavní autoři: Detrez, Iris, Dreesen, Erwin, Van Stappen, Thomas, de Vries, Annick, Brouwers, Els, Van Assche, Gert, Vermeire, Séverine, Ferrante, Marc, Gils, Ann
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2016
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4957447/
https://ncbi.nlm.nih.gov/pubmed/26738756
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ecco-jcc/jjv241
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky